Lipoprotein (a)NCT07579325
Lipid Screening Study
An observational study of Lipoprotein (a), run by University of Central Florida at 1 site in United States.
Trial summary
The purpose of this pilot study is to estimate the prevalence of elevated Lipoprotein (a) in an adult primary care population and to describe the distribution of atherogenic lipid markers within this cohort. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Lipoprotein (a)
- What is being tested?
- Venipuncture
- How many people
- 35 participants
- Where
- 1 siteUnited States
- Study dates
- 5 May 2026to 28 Jul 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: As any adult patient can be enrolled, no pre-screening will be done. UCFH only sees adult patients.
Who may be able to join
- Adults aged 18 years or older
- Receiving care at UCF Health primary care clinic
- Able to understand and provide informed consent and HIPAA authorization
Who cannot join
- Patient self discloses any medical condition that would make venipuncture unsafe
- Pregnant women
Trial locations and contacts
1 site in 1 country.
United States1 site
University of Central Florida
Orlando, Florida, 32827
About this study
Official title: Prospective Screening for Elevated Lipoprotein(a) in an Adult Primary Care Population
The purpose of this pilot study is to estimate the prevalence of elevated Lipoprotein (a) in an adult primary care population and to describe the distribution of atherogenic lipid markers within this cohort. This pilot study will provide preliminary data to inform future cardiovascular risk assessment initiatives in primary care.
- Conditions
- Lipoprotein (a)
- Being tested
- Venipuncture
- Keywords
- lipoprotein (a), HDL and LDL, HDL, LDL, lipid Panel
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
VenipunctureOther
The study procedures include a single venipuncture (10 mL) performed for research purposes to obtain blood samples for laboratory analysis of lipoprotein(a), apolipoprotein B, and a lipid panel with reflex to direct Low-Density Lipoprotein (LDL) cholesterol measurement. The lipid panel includes total cholesterol, triglycerides, High-Density Lipoprotein (HDL) cholesterol, and calculated non-HDL cholesterol and cholesterol/HDL ratio. If triglyceride levels exceed the laboratory threshold for accurate calculation of LDL cholesterol, a direct LDL cholesterol assay will be performed per standard laboratory protocol. In addition, the study includes abstraction of demographic and clinical information from the electronic medical record (EMR), including age, sex, BMI, comorbid conditions, and cardiovascular history. All laboratory analyses will be performed using standard clinical laboratory assays. No investigational drugs or medical devices are being used in this study.
What is being measured
The primary outcome is the main question the study is designed to answer.
Lipoprotein(a) prevalence in Adults
The purpose of this pilot study is to estimate the prevalence of elevated Lipoprotein (a) in an adult primary care population and to describe the distribution of atherogenic lipid markers within this cohort. This pilot study will provide preliminary data to inform future cardiovascular risk assessment initiatives in primary care.
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 May 2026
- Study start5 May 2026
- Primary completion16 Jul 2026
- Study completion28 Jul 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lipoprotein (a)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 35 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Central Florida
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Stephanie Perez, MSN, MBA, ARNP, CLS, BHCN, Principal investigator, University of Central Florida
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07579325
- Sponsor's protocol ID
- STUDY0009025
- Status last verified
- Jul 2026
- First submitted
- 6 May 2026
- Last updated
- 30 Jul 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 30 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective Screening for Elevated Lipoprotein(a) in an Adult Primary Care Population
- ClinicalTrials.gov ID
- NCT07579325
- Acronym / sponsor ID
- STUDY0009025
- Conditions
- Lipoprotein (a)
- Keywords
- lipoprotein (a), HDL and LDL, HDL, LDL, lipid Panel
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 35 participants (actual)
- Lead sponsor
- University of Central FloridaUniversity, hospital or other
- Study start
- 5 May 2026 (actual)
- Primary completion
- 16 Jul 2026 (actual)
- Study completion
- 28 Jul 2026 (actual)
- First posted
- 12 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this pilot study is to estimate the prevalence of elevated Lipoprotein (a) in an adult primary care population and to describe the distribution of atherogenic lipid markers within this cohort. This pilot study will provide preliminary data to inform future cardiovascular risk assessment initiatives in primary care.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- As any adult patient can be enrolled, no pre-screening will be done. UCFH only sees adult patients.
Key inclusion criteria (3 listed)
- Adults aged 18 years or older
- Receiving care at UCF Health primary care clinic
- Able to understand and provide informed consent and HIPAA authorization
Key exclusion criteria (2 listed)
- Patient self discloses any medical condition that would make venipuncture unsafe
- Pregnant women
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| VenipunctureThe study procedures include a single venipuncture (10 mL) performed for research purposes to obtain blood samples for laboratory analysis of lipoprotein(a), apolipoprotein B, and a lipid panel with reflex to direct Low-Density Lipoprotein (LDL) cholesterol measurement. The lipid panel includes total cholesterol, triglycerides, High-Density Lipoprotein (HDL) cholesterol, and calculated non-HDL cholesterol and cholesterol/HDL ratio. If triglyceride levels exceed the laboratory threshold for accurate calculation of LDL cholesterol, a direct LDL cholesterol assay will be performed per standard laboratory protocol. In addition, the study includes abstraction of demographic and clinical information from the electronic medical record (EMR), including age, sex, BMI, comorbid conditions, and cardiovascular history. All laboratory analyses will be performed using standard clinical laboratory assays. No investigational drugs or medical devices are being used in this study. | Other | – |
Primary outcome
Lipoprotein(a) prevalence in Adults
Time frame: 3 months
The purpose of this pilot study is to estimate the prevalence of elevated Lipoprotein (a) in an adult primary care population and to describe the distribution of atherogenic lipid markers within this cohort. This pilot study will provide preliminary data to inform future cardiovascular risk assessment initiatives in primary care.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Jul 2026.
Related trials for Lipoprotein (a)
Recruiting
Metabolic Impact of VLCPUFA-Rich Fish Oil: A Clinical Study on Omega-3 Index Enhancement in Healthy Individuals
Fatty Acids, Omega-3, Fish Oils
RecruitingPhase 2
A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)
Lipoprotein(a)
Recruiting
Test 2 Treat: Can we Improve the Testing and Treatment of High Cholesterol in Patients Who Have Been Hospitalized for a Cardiac Event by Providing Education to Doctors and Patients?
ASCVD, LDL-C
Active, not recruitingPhase 2
Phase 2 Study of Kylo-11 in ASCVD Patients With Elevated Lp(a)
Lipoprotein Disorder
Active, not recruitingPhase 2
A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
Hypercholesterolemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Stephanie Perez, MSN, MBA, ARNP, CLS, BHCN principal investigator
University of Central Florida
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Lipoprotein (a), run by University of Central Florida at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Lipoprotein(a) prevalence in Adults (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jul 2026.